Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression Profiling of Formalin-Fixed Parafin-Embedded Primary Breast Tumors Whole Genome DASL

ABSTRACT: HER2-positive and HER2-negative samples are compared within this Whole Genome Platform Two-class comparison

ORGANISM(S): Homo sapiens

SUBMITTER: Keith Anderson

PROVIDER: E-GEOD-25233 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL® platform.

Reinholz Monica M MM Eckel-Passow Jeanette E JE Anderson S Keith SK Asmann Yan W YW Zschunke Michael A MA Oberg Ann L AL McCullough Ann E AE Dueck Amylou C AC Chen Beiyun B April Craig S CS Wickham-Garcia Eliza E Jenkins Robert B RB Cunningham Julie M JM Jen Jin J Perez Edith A EA Fan Jian-Bing JB Lingle Wilma L WL

BMC medical genomics 20101220

<h4>Background</h4>The cDNA-mediated Annealing, extension, Selection and Ligation (DASL) assay has become a suitable gene expression profiling system for degraded RNA from paraffin-embedded tissue. We examined assay characteristics and the performance of the DASL 502-gene Cancer Panel v1 (1.5K) and 24,526-gene panel (24K) platforms at differentiating nine human epidermal growth factor receptor 2- positive (HER2+) and 11 HER2-negative (HER2-) paraffin-embedded breast tumors.<h4>Methods</h4>Bland- ...[more]

PMID: 21172013

Similar Datasets

Expression Profiling of Formalin-Fixed Parafin-Embedded Primary Breast Tumors DASL Cancer Panel

Project description:HER2-positive and HER2-negative samples are compared within this DASL Cancer Panel Platform Two-class comparison

2010-12-20 | E-GEOD-25231 | biostudies-arrayexpress

Expression Profiling of Formalin-Fixed Parafin-Embedded Primary Breast Tumors

Project description:This SuperSeries is composed of the following subset Series: GSE25231: Expression Profiling of Formalin-Fixed Parafin-Embedded Primary Breast Tumors DASL Cancer Panel GSE25233: Expression Profiling of Formalin-Fixed Parafin-Embedded Primary Breast Tumors Whole Genome DASL Refer to individual Series

2010-12-20 | E-GEOD-25234 | biostudies-arrayexpress

Expression Profiling of Formalin-Fixed Parafin-Embedded Primary Breast Tumors Whole Genome DASL

Project description:HER2-positive and HER2-negative samples are compared within this Whole Genome Platform

2010-12-20 | GSE25233 | GEO

Expression Profiling of Formalin-Fixed Parafin-Embedded Primary Breast Tumors DASL Cancer Panel

Project description:HER2-positive and HER2-negative samples are compared within this DASL Cancer Panel Platform

2010-12-20 | GSE25231 | GEO

Expression Profiling of Formalin-Fixed Parafin-Embedded Primary Breast Tumors Whole Genome DASL

Project description: Not available

| S-ECPF-GEOD-25233 | biostudies-other

Expression Profiling of Formalin-Fixed Parafin-Embedded Primary Breast Tumors DASL Cancer Panel

Project description: Not available

| S-ECPF-GEOD-25231 | biostudies-other

Gene Expression Profiling of Formalin Fixed Paraffin Embedded Familial Breast Tumours Using the Whole Genome-DASL Assay

Project description: Not available

| S-ECPF-GEOD-21921 | biostudies-other

Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL® platform.

Project description: Not available

| S-EPMC3022545 | biostudies-literature

Identification of HER2 peptides for quantification in formalin-fixed paraffin-embedded breast cancer tissues

Project description:The ability to accurately quantify proteins in formalin-fixed paraffin-embedded (FFPE) tissues using targeted mass spectrometry opens exciting perspectives for biomarker discovery. We have developed and evaluated a selected reaction monitoring (SRM) assay for the human receptor tyrosine-protein kinase erbB-2 (HER2) in FFPE breast tumors. Peptide candidates were identified using an untargeted mass spectrometry approach in relevant cell lines. A selected reaction monitoring (SRM) assay was developed for the six best candidate peptides and evaluated for linearity, precision and lower limit of quantification. The six HER2 peptides of interest were then quantified by SRM in a cohort of 40 archival formalin-fixed paraffin-embedded tumor tissues from women with invasive breast carcinomas, showing different levels of HER2 gene amplification. Finally, the agreement was tested between data generated by SRM and data generated using standard clinical pathology methods, namely immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). The high agreement observed indicates that SRM is a suitable method to quantify peptides from FFPE material, and therefore represents a powerful approach for biomarker discovery studies.

2015-07-16 | PXD002281 | Pride

Transcription profiling of human formalin-fixed paraffin-embedded breast cancer core biopsies

Project description:The routine workflow for invasive cancer diagnostics is based on biopsy processing by formalin fixation and subsequent paraffin embedding. Formalin-fixed paraffin-embedded (FFPE) tissue samples are easy to handle, stable and particularly suitable for morphologic evaluation, immunohistochemistry and in situ hybridization. However, it has become a paradigm that these samples cannot be used for genome-wide expression analysis with microarrays. To oppose this view, we present a pilot microarray study using FFPE core needle biopsies from breast cancers as RNA source. We found that microarray probes interrogating sequences near the poly-A-tail of the transcribed genes were well suitable to measure RNA levels in FFPE core needle biopsies. For the ER and the HER2 gene, we observed strong correlations between RNA levels measured in these probe sets and protein expression determined by immunohistochemistry (p = 0.000003 and p = 0.0022). Further, we have identified a signature of 364 genes that correlated with ER protein status and a signature of 528 genes that correlated with HER2 protein status. Many of these genes (ER: 60%) could be confirmed by analysis of an independent publicly available data set. Finally, a hierarchical clustering of the biopsies with respect to three recently reported gene expression grade signatures resulted in widely stable low and high expression grade clusters that correlated with the pathological tumor grade. These findings support the notion that clinically relevant information can be gained from microarray based gene expression profiling of FFPE cancer biopsies. This opens new opportunities for the integration of gene expression analysis into the workflow of invasive cancer diagnostics as well as translational research in the setting of clinical studies. Experiment Overall Design: RNA from 24 breast cancer biopsies extracted with kit A, RNA from 6 breast cancer biopsies extracted with kit B

2008-10-20 | E-GEOD-11001 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data